At a glance
| Abbreviation | DENV-2, DENV-1, DENV-3, DENV-4 |
|---|---|
| ICTV species | Orthoflavivirus denguei |
| Family | Flaviviridae |
| Baltimore class | IV — (+)ssRNA |
| Human infection | Human infection recorded; pattern not classified |
Also called: dengue virus type 2; dengue virus type 1; dengue virus type 3; dengue virus type 4; Orthoflavivirus denguei
Riboviria › Kitrinoviricota › Flasuviricetes › Amarillovirales › Flaviviridae › Orthoflavivirus
What it is
Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not hand-edited; a correction means re-running the fetch against a newer release.
| Realm | Riboviria |
|---|---|
| Kingdom | Orthornavirae |
| Phylum | Kitrinoviricota |
| Class | Flasuviricetes |
| Order | Amarillovirales |
| Family | Flaviviridae |
| Genus | Orthoflavivirus |
| ICTV identifier | ICTV19990820 |
| NCBI taxon | 3052464 |
| Exemplar isolate | U87411 |
Host evidence
- human: 50,752 GenBank records
- dog: 5 GenBank records (flagged for review)
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
Not searched yet. No country-level occurrence data has been curated for this virus. The WHO reported-case data on this site covers a limited set of diseases; a virus outside it gets no map rather than an empty one.
What it does
Each figure is the one its source printed, with the sentence it came from. Nothing is recomputed, averaged or converted.
Burden
| Measure | As the source states it | Source |
|---|---|---|
| Annual Cases | 100-400 million infections occurring each yearglobal | quoteAbout half of the world's population is now at risk of dengue, with an estimated 100-400 million infections occurring each year. Dengue and severe dengue fact sheet · source · verified 2026-10-30 |
| Annual Cases | 14.6 million reported casesglobal · 2024 | quoteGlobal burden The incidence of dengue has grown dramatically worldwide in recent decades, with the number of cases reported to WHO increasing from 505 430 cases in 2000 to 14.6 million in 2024. Dengue and severe dengue fact sheet · source · verified 2026-10-30 |
Transmission and spread
| Measure | As the source states it | Source |
|---|---|---|
| Incubation Period | 4-10 daysglobal | quoteIf symptoms occur, they usually begin 4-10 days after infection and last for 2-7 days. Dengue and severe dengue fact sheet · source · verified 2026-10-30 |
Vaccines
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| Dengue Tetravalent Vaccine, Live | See FDA listing | Not searched yet | Routine immunisation | Approved | US: approved | — | candidateId fda-dengue-tetravalent-vaccine-live (targetDisease 'Dengue |
In development
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| TDV | Takeda | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT06665035 NCT06579755 | candidateId ctgov-tdv-takeda (targetDisease 'Dengue'); stage copied, n |
| Tetravalent Dengue Vaccine (TDV) | Takeda | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07047521 | candidateId ctgov-tetravalent-dengue-vaccine-tdv-takeda (targetDisease |
| V181 | Merck Sharp & Dohme LLC | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07013487 | candidateId ctgov-v181-merck-sharp-dohme-llc (targetDisease 'Dengue'); |
| CYD Dengue Vaccine | Sanofi Pasteur, a Sanofi Company | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT02992418 | candidateId ctgov-cyd-dengue-vaccine-sanofi-pasteur-a-sanofi-company ( |
Antivirals
Not searched yet. No US-approved antiviral for this virus was found in the openFDA drug label endpoint. Only US labels were searched, and only drugs the FDA classes as antivirals.
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are on the label and in national guidelines. This page does not give medical advice and does not render dosing. A development stage is not a measure of how well something works.
Related on this site
- Vaccine pipeline — candidates listed under “Dengue”
- Other Flaviviridae viruses
- Veterinary vaccines for this virus — animals, kept separate on purpose